Pharma poised for another painful quarter
Updated : April 09, 2018 05:38 PM IST
Analysts are factoring in a 2-5% decline in the US revenues on a constant currency basis
Companies such as Sun, Lupin and Glenmark could face tough competition in the US this quarter.
Domestic markets expected to perform better.